Dianabol vs Liothyronine (T3)
Well Studied vs FDA Approved
avoid Mechanism-based · 60% Both Dianabol and Liothyronine (T3) carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Dianabol Liothyronine (T3)
Weight 300.44 Da 650.97 Da
Half-life ~4-6 hours ~1 day
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Thyroid hormone (C15H12I3NO4)
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Liothyronine (T3)
01 Direct and rapid increase in basal metabolic rate
02 Enhanced fat oxidation and lipolysis
03 Improved energy levels and reduction of hypothyroid fatigue
04 Faster-acting than T4 with effects noticeable within hours to days
05 Useful when peripheral T4-to-T3 conversion is impaired (illness, caloric deficit, stress)
06 Supports body temperature regulation and thermogenesis
07 Can improve cognitive clarity and reduce brain fog associated with low thyroid function
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Liothyronine (T3)
Tachycardia and palpitations (increased heart rate, especially at higher doses)
Anxiety, nervousness, and irritability
Insomnia and disrupted sleep architecture
Increased sweating and heat intolerance
Tremor (fine hand tremor, similar to hyperthyroid presentation)
Increased appetite despite accelerated metabolism
Loose stools or increased bowel frequency
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Untreated adrenal insufficiency (must correct cortisol deficiency before starting T3)
Acute myocardial infarction or unstable angina
Thyrotoxicosis or untreated hyperthyroidism
Known hypersensitivity to liothyronine or any tablet excipients
Uncorrected adrenal cortical insufficiency (risk of adrenal crisis)
Research Evidence
Dianabol Liothyronine (T3)
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest 2017 September 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.